SCHEMBL20596070

SCHEMBL20596070

COc1ccc(-c2cccc3c2CN(Cc2nc4ccc(Cl)cc4[nH]2)C3=O)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AMY1A P0DUB6 2/20 0.43
▸ F10 P00742 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ BRS3 P32247 2/20 0.40
▸ RAB9A P51151 1/20 0.39
▸ DPP4 P27487 1/20 0.39
▸ DPP8 Q6V1X1 1/20 0.39
▸ DPP9 Q86TI2 1/20 0.39
▸ DRD4 P21917 1/20 0.38
▸ AURKA O14965 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ ERBB2 P04626 1/20 0.38
▸ GRIN1 Q05586 1/20 0.37
▸ GRIN2B Q13224 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ CXCR2 P25025 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595883 0.93 DPP4 (0.39) AMY1ARAB9ADPP4DPP8DPP9
SCHEMBL30145153 0.84 MARS2 (0.49) DPP4DPP8DPP9
SCHEMBL23391438 0.84 MARS2 (0.49) DPP4DPP8DPP9
SCHEMBL20595825 0.82 HPGD (0.33) DPP4DPP8DPP9EGFRGRIN1
SCHEMBL20595887 0.81 TNKS (0.36) DPP4DPP8DPP9GRIN1GRIN2B
SCHEMBL23391546 0.79 IDH1 (0.37) DPP4DPP8DPP9ERBB2GRIN1
SCHEMBL23391415 0.78 DPP4 (0.36) DPP4DPP8DPP9AURKA
SCHEMBL20595700 0.78 DPP4 (0.37) DPP4DPP8DPP9AURKA
SCHEMBL23391457 0.76 HSP90AA1 (0.36) DPP4DPP8DPP9AURKAKDR
SCHEMBL30145116 0.76 HSP90AA1 (0.36) DPP4DPP8DPP9AURKAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US claimed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR AMY1A 3656/4885F10 4394/4885POLB 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback